A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

Trial Identifier:	PT010018
Sponsor:	Pearl Therapeutics, Inc.
NCTID::	NCT03250182
Start Date:	August 2017
Primary Completion Date:	December 2017
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States of America, FL	Clearwater, FL, United States of America, 33765

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.